Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide + methotrexate + prednisolone + vincristine
- Development stage
- Unknown
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
This is a combination chemotherapy regimen used primarily for the treatment of aggressive non-Hodgkin lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). The regimen consists of multiple cytotoxic agents that work through different mechanisms to target rapidly dividing cancer cells. When combined with rituximab (as R-MACOP-B) and followed by involved-field radiation therapy in patients with bulky presentation, it has shown high efficacy in young patients with low-risk DLBCL, with studies reporting 7-year progression-free survival of 91% and overall survival of 94%.
- Other names
- methotrexate + doxorubicin + cyclophosphamide + vincristine + prednisone + bleomycin (when bleomycin is included)
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide + methotrexate + prednisolone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide + methotrexate + prednisolone + vincristine.